Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Moderate weight loss of 5 to 10% ameliorates cardiovascular risk factors such as hyperglycemia, hypertension, and dyslipidemia
We exclude weight loss, the entire anti-obesity category
Rachakonda L, Bapatla AK, Mohanty SP, Kougianos E
J., Olpin, S., Andresen, B
Glow with Confidence
The FDA has approved Wegovy (semaglutide) and Zepbound (tirzepatide) specifically for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia
US$ 22.93
US$ 27.97
US$ 22.90
US$ 22.10
US$ 22.79
US$ 25.04
